Genome-wide association studies (GWAS) of breast cancer defined by hormone receptor status have revealed loci contributing to susceptibility of estrogen receptor (ER)-negative subtypes. 
NCI Breast and Prostate Cancer Cohort Consortium (BPC3) (2,188 ER-negative cases; 25,519 controls of
European ancestry), Triple Negative Breast Cancer Consortium (TNBCC) (1,562 triple negative cases; 3,399 controls of European ancestry) and African American Breast Cancer Consortium (AABC) (1,004 ER-negative cases; 2,745 controls). We performed in silico replication of 86 SNPs at P ≤1x10 -5 in an additional 11,209 breast cancer cases (946 with ER-negative disease) and 16,057 controls of Japanese, Latino and European ancestry. We identified two novel loci for breast cancer at 20q11 and 6q14. SNP rs2284378 at 20q11 was associated with ER-negative breast cancer (combined two stage OR=1.16; P= 1.1x10 -8 ) but showed a weaker association with overall breast cancer (OR=1.08, P=1.3x10 -6 ) based on 17,869 cases and 43,745 controls and no association with ER-positive disease (OR=1.01, P=0.67) based on 9,965 cases and 22,902 controls. Similarly, rs17530068 at 6q14 was associated with breast cancer (OR=1.12; P= 1.1x10 -9 ), and with both ER-positive (OR=1.09; P=1.5x10 -5 ) and ER-negative (OR=1.16,
P=2
.5x10 -7 ) disease. We also confirmed three known loci associated with ER-negative (19p13) and both ER-negative and ER-positive breast cancer (6q25 and 12p11). Our results highlight the value of largescale collaborative studies to identify novel breast cancer risk loci. 
INTRODUCTION
Breast cancer is a heterogeneous disease and has multiple histological and molecular subtypes, likely with distinct etiologies. Tumors that lack expression of the estrogen receptor (ER) tend to have more aggressive disease, higher histological grade, and lower survival rates (1) . ER-negative breast cancer is more common in women of African ancestry, accounting for as much as 40% of cases in African
American women compared with 15-20% in women of European ancestry. The etiologic heterogeneity between breast cancer subtypes is supported by different associations with ER-positive versus ERnegative disease for many of the known breast cancer risk factors (such as reproductive factors and BMI) (2) . Tumors in women with BRCA1 mutations are predominantly ER-negative, while tumors in BRCA2 mutation carriers are predominantly ER-positive(3). Furthermore, genome-wide association studies have identified multiple common genetic variants more strongly associated with ER-positive than ER-negative breast cancer (4) . Through collaborative efforts, we recently identified risk loci on 5p15 and 19p13 that are associated specifically with ER-negative and triple negative (TN) (ER-negative, progresterone (PR)-negative and HER2-negative) breast cancer(5-7).
In order to identify genetic loci associated with risk of ER-negative breast cancer, we conducted a meta-analysis of three GWAS of ER-negative breast cancer, comprising 4,754 cases and 31,663 controls with further replication in an additional 11,209 cases (946 with ER-negative disease) and 16,057 controls.
RESULTS
The meta-analysis included GWAS of ER-negative breast cancer (4 (eukaryotic translation initiation factor 2, subunit 2 beta) and ~100kb upstream of ASIP (agouti signaling protein), and is in high linkage disequilibrium (r 2 =0.96 and D'=1) with rs4911414, which has been associated with melanoma and basal cell carcinoma(9) (Supplementary Figure 2) . The T allele at rs2284378 was associated with an increased ER-negative breast cancer risk (OR>1) in all racial/ethnic populations, except Japanese (OR=0.99) ( Table 1) . However this group had the smallest sample size.
Furthermore, no significant evidence of heterogeneity was observed by race (P=0.28) or study (P=0.54) ( Table 6 ).
We also evaluated associations for 25 known breast cancer risk markers in European-ancestry women from our study (Supplementary Table 7 and Supplementary Figure 4) . 
DISCUSSION
We present results from the largest meta-analysis to date to specifically focus on ER-negative disease. We identify two novel loci for breast cancer: 20q11 associated with ER-negative and triple negative, but not ER-positive breast cancer, and 6q14 associated with both ER-positive and ER-negative breast cancer. In addition, we confirm three known regions previously associated with ER-negative (19p13) or ERnegative and ER-positive breast cancer (6q25 and 12p11). Correction for genomic control results in similar but attenuated findings for 20q11-rs2284378 (P GC =2.4x10
-8
) and 6q14-rs17530068 (P GC =3.2x10
The novel association at 20q11 with ER-negative breast cancer spans the ASIP, RALY and EIF2S2 genes. Agouti signaling protein (product of the ASIP gene) was first described to inhibit melanogenesis in human melanocytes in 1997 (11) . ASIP is a melanocortin 1 receptor (MC1R) ligand that antagonises the function of the transmembrane receptor (12) . The variants we identified at 20q11 for breast cancer are highly correlated with variants previously associated with pigmentation traits as well as risk of both cutaneous melanoma and basal cell carcinoma(9), suggesting a possible biological link between these cancers. Further studies have confirmed the importance of the genetic variation spanning the ASIP locus, where a variant at 20q11 showed the strongest association with pigmentation and was implicated in a probable linkage disequilibrium (LD) with variants within an ASIP regulatory region (13) .
EIF2S2 encodes eukaryotic translation initiation factor 2, subunit 2 beta, which is involved in early steps of protein synthesis by forming a ternary complex with GTP and initiator tRNA. The deletion of Eif2s2 has been associated with suppression of testicular germ cell tumor incidence and recessive lethality in mice (14) . The agouti-yellow (AV) deletion is a genetic modifier known to suppress testicular germ cell tumor susceptibility in mice and humans. The AV mutation deletes both RALY and Eif2s2, and induces the ectopic expression of agouti, all of which are potential testicular germ cell tumor-modifying variations Table 9 ). In addition to expression, Table   10 ). Additional studies of both of these novel regions will be necessary to identify the underlying biologically relevant variant/s. 
BPC3 GWAS genotyping was conducted at three genotyping centers (NCI Core Genotyping
Facility, USA; University of Southern California, USA; and Imperial College London, UK). Subjects from CPSII, EPIC, MEC, PLCO, and PBCS were genotyped using the Illumina Human 660k-Quad SNP array(Illumina, Inc), NHSI/NHSII and part of the PLCO study were genotyped previously using the Illumina Human 550 SNP array(Illumina, Inc) (20) . SNPs were filtered and removed based on deviations from Hardy-Weinberg proportions in control subjects (p<10e-5), autosomal SNPs with MAF of less than 5% and completion rate less than 95%. Samples were excluded based on genotyping call rates less than 95% (n=195), samples with extreme heterozygosity were excluded from the analysis (n=35), sex discordance (n=3), unexpected duplicates and relatedness (n=6), Subjects with evidence of significant non-European ancestry and population structure were also excluded. Non-European ancestry was assessed utilizing a subset of unlinked, population informative SNPs (21) . Individuals determined to have less than 80% European ancestry were excluded from future analyses (n=16). The average concordance rate of blinded duplicates was 99.95%. In order to resolve a more detailed population substructure, PCA was conducted using struct.pca module of GLU (http://code.google.com/p/glu-genetics/). PCA was only performed in subjects with over 80% European ancestry. Furthermore, 958 controls from NHS (CGEMS)
were removed from BPC3 analyses due to overlap between TNBCC and BPC3 studies. The overall number of cases and controls after all exclusions which contributed to the stage 1 analysis were 1,998 cases and 2,305 controls.
The WHS cohort subjects in BPC3 were previously genotyped using the Human-Hap300 Duo- These studies were imputed separately. For the combined analysis, the control set was divided randomly between the two studies, in proportion to the size of case series, to provide disjoint strata. Estimated perallele ORs and standard errors were generated from the imputed genotypes using Probabel (25) .
SNP rs2284378 and rs17530068 were genotyped in all stage 2 studies except SFBCS and NC-BCFR where they were imputed. Both SNPs were genotyped by TaqMan in 483 samples from these studies and genotype concordance versus imputed genotypes was 93.3% for rs2284378 and 94.9% for rs17530068.
Taqman gentoyping in BPC3 for SNP rs2284378 and SNP rs17530068
In In AABC, we tested for gene dosage effects in models adjusted for age, study and eigenvectors 1-10.
Odds ratios (OR) and 95% confidence intervals (95% CI) were estimated using unconditional logistic regression. In TNBCC, unconditional logistic regression was used to assess single SNP associations also assuming a log-additive model, adjusting for country and the first two principal components. In BPC3, unconditional logistic regression model was used to assess single SNP associations adjusting for age categories and the top 6 eigenvectors.
In both AABC and TNBCC, phased haplotype data from the founders of the CEU and YRI HapMap Phase 2 samples (build 21) were used to infer LD patterns in order to impute untyped markers.
For BPC3, Hapmap Phase 2 (release 21) and Hapmap Phase 3 were used to impute untyped markers. For all studies, genome-wide imputation was carried out using the software MACH. Filtered from the analysis were SNPs with Rsq<0.3 and MAF <1%.
We conducted a fixed effect meta-analysis of AABC, TNBCC and BPC3 using the inverse variance weighted method. The number of SNPs available for meta-analysis from AABC, TNBCC and BPC3 in stage 1 were 3,055,415, 2,134,490 and 245,3207 respectively. The union of these three data sets was meta-analyzed using the program METAL. We conducted in silico replication of 86 SNP with pvalues ≤ 10 -5 in stage 1 in the stage 2 studies, and a meta-analysis of these SNPs from stage 1 and 2 for both ER-negative and overall breast cancer. P-values from our top two loci were corrected for genomic inflation (P GC ) using the lambda value from the overall meta-analysis. Testing for heterogeneity by study was evaluated using the Q-statistic. Case-only analyses were performed to test for differences in the association by tumor subtypes, study and race/ethnicity.
The association between risk scores of 25 previously-identified breast cancer risk alleles and risk of breast cancer in our samples was calculated using meta-regression, assuming the per-allele odds ratio was constant across the markers analyzed. This is equivalent to combining the summary log odds ratio estimates at independent loci using inverse-variance weighted meta-analysis. The overlap between subjects contributing to this study and those contributing to previous studies varied from marker to marker (e.g. the TNBCC contributed to the initial report on rs8170 (5) and the BPC3 and TNBCC contributed to the initial report on the TERT locus (6).Thus, the results could be overestimates since some of the studies here contributed to the discovery of these 25 loci.
Functional analysis
Expression quantitative trait loci (eQTL) were assessed for all SNPs in the chromosome 6 and 20 loci using the GTEX database (http://www.ncbi.nlm.nih.gov/gtex/GTEX2/gtex.cgi), University of Chicago eQTL Browser (http://eqtl.uchicago.edu) and Genevar (http://www.sanger.ac.uk/resources/software/genevar/) (26) In an attempt to identify functionality at the two novel breast cancer risk loci, we used the opensource R/Bioconductor package FunciSNP version 0.99 (27) , which systematically integrates the 1,000
Genomes Project SNP data (April 2012 data release) with chromatin features of interest. For each of the two novel breast cancer markers, we analyzed all SNPs with an r 2 value > 0.5 with each index SNP in the 1,000 Genomes Project EUR populations in a 1MB window around each index variant. We assessed whether these SNPs were co-located with 12 different chromatin features generated by next-generation sequencing technologies, which capture open chromatin regions, promoters, and enhancers genome-wide in human mammary epithelial cells (HMEC) as well as known DNaseI hypersensitive locations, FAIREseq peaks, and CTCF binding sites from more than 100 different cell types, which were collected in ENCODE data (28) . We utilized the UCSC Genome Browser (http://genome.ucsc.edu/) to illustrate the correlated SNPs, which overlap chromatin features as well as chromatin feature tracks (Supplemental 
